NewsRelease
ResearchArticle CitesHemogloBind™for Removing Colorimetric Assay Interferences
MONMOUTHJUNCTION, NJ, July28, 2016 -- Biotech Support Group reports on a recent researcharticle describingthe simplicity and efficiency of their hemoglobin depletiontechnology for removing colorimetric interferences in measuringcholinesteraseactivity. The citation is:
ThomasH. Snider, Kevin G. McGarry, Michael C. Babin, David A. Jett, GennadyE. Platoff Jr., and David T. Yeung. AcuteToxicity of Phorate Oxon by oral gavage in the Sprague-Dawley rat.Fundam.Toxicol. Sci. Vol. 3, No.5, 195-204, 2016.
Thearticle describes studies of the oral toxicity of Phorate Oxon withemphasis on gender and age-related effects in rats. The authors usedHemogloBind™ as part of the protocol to measure cholinesteraseactivity. The article states “…80 µl aliquots of whole bloodwere removed, diluted and treated with HemogloBind™ to removehemoglobin for later assay to detect cholinesterase activity…
“Thisis now the 5thresearch article validating the removal efficiency of HemogloBind™for depleting hemoglobin prior to cholinesterase measurements. Thecolorimetric interferences of hemoglobin are quite common in manyenzymatic assays so these studies are consistent in that they allshow an exquisite selectivity profile in many different animals”states Swapan Roy, Ph.D., President and Founder of Biotech SupportGroup.
Formore information on HemogloBind™, visit:
http://www.biotechsupportgroup.com/HemogloBind-Hemoglobin-Depletion-From-Hemolyzed-p/h0145.htm
AboutBiotech Support Group LLC
Convergingwith cultural and technological disruptions forthcoming inhealthcare, Biotech Support Group develops methods for cost effectiveand efficient sample prep essential for these expanding markets.Following a tiered business strategy, the company continues itsgrowth in the consumable research products area supporting therapidly expanding installation of LC-MS instrument and computationalinfrastructure. For this market, key products include: AlbuVoid™and AlbuSorb™ for albumin depletion, Cleanascite™ for lipidadsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal,and NuGel™ for functional proteomics. From these innovations, thecompany has acquired knowledgebase and biomarker intellectualproperty assets that support discoveries of protein markers fromblood, with special emphasis on early detection and personalizedmedical decisions for cancer patients. For more information, goto http://www.biotechsupportgroup.com
Contact:
Dr. Swapan Roy & Matthew Kuruc
Biotech Support Group LLC
1 Deer Park Drive, Suite M
Monmouth Junction NJ 08852
732-274-2866 Worldwide
800-935-0628 North America
[email protected]
http://www.biotechsupportgroup.com
